The metabolic syndrome in polycystic ovary syndrome

被引：0
作者：
P. A. Essah
J. E. Nestler
机构：
[1] Division of Endocrinology and Metabolism,Department of Internal Medicine
[2] Virginia Commonwealth University,Department of Obstetrics, Medical College of Virginia
来源：
Journal of Endocrinological Investigation | 2006年 / 29卷
关键词：
Polycystic ovary syndrome; metabolic syndrome; insulin resistance; hyperandrogenism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Much overlap is present between the polycystic ovary syndrome (PCOS) and the metabolic syndrome. This article reviews the existing data regarding the prevalence, characteristics, and treatment of the metabolic syndrome in women with PCOS. The prevalence of the metabolic syndrome in PCOS is approximately 43–47%, a rate 2-fold higher than that for women in the general population. High body mass index and low serum HDL cholesterol are the most frequently occurring components of the metabolic syndrome in PCOS. The pathogenic link between the metabolic syndrome and PCOS is most likely insulin resistance. Therefore, the presence of the metabolic syndrome in PCOS suggests a greater degree of insulin resistance compared to PCOS without the metabolic syndrome. Obesity, atherogenic dyslipidemia, hypertension, impaired fasting glucose/impaired glucose tolerance, and vascular abnormalities are all common metabolic abnormalities present in PCOS. Lifestyle modification has proven benefit and pharmacological therapy with insulin-sensitizing agents has potential benefit in the treatment of the metabolic syndrome in women with PCOS. (J. Endocrinol. Invest. 29: 270–280, 2006)
引用
收藏
页码：270 / 280
页数：10
相关论文
共 244 条
[1]  
Knochenhauer ES(1998)Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study J Clin Endocrinol Metab 83 3078-82
[2]  
Key TJ(2004)Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 19 41-7
[3]  
Kahsar-Miller M(1997)Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocr Rev 18 774-800
[4]  
Waggoner W(1996)Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome N Engl J Med 335 617-23
[5]  
Boots LR(2005)Polycystic ovary syndrome N Engl J Med 352 1223-36
[6]  
Azziz R(1999)Hypertriglyceridemia, insulin resistance, and the metabolic syndrome Am J Cardiol 83 25-803
[7]  
Dunaif A(2003)Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors Diabetes Care 26 2796-304
[8]  
Nestler JE(2005)The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 28 2289-52
[9]  
Jakubowicz DJ(2005)Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2735-21
[10]  
Ehrmann DA(2000)Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women Arterioscler.Thromb Vasc Biol 20 2414-93
12345678910